A study assessing the discrepancies in HER2 testing between unaccredited local laboratories and an accredited central testing center reported that 85% of IHC 0 scored in local laboratories were IHC 1+ or 2+, suggesting the role of laboratory accreditation in distinguishing subgroups of HER2-low breast cancer [76]. The gene discussed is ERBB2; the disease is breast carcinoma.